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Pseudomonas aeruginosa bacteremia in 
patients undergoing liver transplantation: An 
emerging problem 
Joyce A. Korvick, MD, J. Wallis Marsh, MD, Thomas E. Starzl, MD, and 
Victor L. Yu, MD, Pittsburgh, Pa. 
In our institution, Pseudomonas aeruginosa bacteremia appeared to occur with 
increasing frequency in patients undergoing liver transplantation. We thus conducted a 
prospective study to define risk factors and outcome in these patients. Over a 19-month 
period 6% of liver transplants were followed by Pseudomonas bacteremia. The mean 
age was 46 years (range, 24 to 67 years). The interval between transplantation and 
onset of bacteremia was 3 to 372 days (mean, 80). The incidence of Pseudomonas 
bacteremia in liver transplants was three times that of other transplants (heart, lung, 
kidney). Ninety one percent of infections were nosocomial. Polymicrobial bacteremia 
occurred in 30% of episodes. The portal of entry was respiratory in 30%, abdominal in 
35%, and biliary in 13%. Four patients had recurrent Pseudomonas bacteremia: liver 
abscess (1), biliary obstruction (2), subhepatic abscess (1). Survival at 14 days was 
70%. Survival rates were significantly lower for patients with hypotension, on 
mechanical ventilators, and increasing severity of illness (p < 0.05). Survival was 
higher when bacteremia occurred within the first 30 days after transplantation 
compared to after 30 days. A large number (43.4%) of Pseudomonas bacteremias 
occurred after transplant surgery or biliary tract manipulation, while the patient was 
receiving a prophylactic regimen of cefotaxime and ampicillin. P. aeruginosa is an 
important pathogen in the liver transplant recipient; prevention may be possible for a 
subgroup of patients with the use of prophylactic antibiotics with activity against P. 
aeruginosa. (SURGERY 1991;109:62-8.) 
From the Departments of Medicine and Surgery, University of Pittsburgh, Pittsburgh, Pa. 
PSEUDOl'vIONAS AHRUGINOSA is a well-established cause 
of bacteremia in hospitalized and immunosuppressed 
patients. At the University of Pittsburgh, P. aeruginosa 
bacteremia has been seen with increasing frequency in 
patients undergoing orthotopic liver transplantation. 
During one 9-month period, 25% (13/51) of Pseudo-
monas bacteremias occurring in our hospital occurred in 
liver transplant recipients compared to 27% (14/51) in 
the neutropenic patient with underlying malignancy. 
Significantly fewer Pseudomonas bacteremias were seen 
in kidney (three patients) or heart transplant recipients 
(one patient) during this same period. 
Thus we initiated a prospective study of liver trans-
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plant recipients who developed P. aeruginosa bactere-
mia to define the demographics and risk factors to elu-
cidate those factors that might improve survival. 
MATERIAL AND METHODS 
Study population. All liver transplant recIpients 
with a positive blood culture for P. aeruginosa were fol-
lowed prospectively by an infectious disease physician 
(J.A.K.) and transplant surgeon (J.W.M.) until the 
time of death or discharge from hospital. Surviving pa-
tients were then followed indefinitely by the surgical 
investigators (J.W.M., T.E.S.). The study period was 
19 months (November 1985 to May 1987). Blood cul-
tures were processed by the BACTEC automated blood 
culture system (Johnston Laboratories, Towson, Md.). 
Degree of illness was quantified as follows: temperature 
> 39° C (2 points), mental status [disorientation (1 
point), stupor (2 points), or coma (4 points)], hypoten-
sion (2 points), mechanical respiratory support (2 
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points), and cardiac arrest (4 points). Patients were 
considered 4+ ill if they accumulated 2:4 points within 
the 72 hours before identification of bacteremia. 
Immunosuppression. Cyclosporin A and prednisone 
dosage schedules were administered as previously 
reported.1 On the day of surgery, intravenous cyclos-
porin A (6 mg/kg/day) was initiated. The serum con-
centrations were maintained at 500 to 1000 ng/ml 
(whole blood radioimmunoassay). 
Methylprednisolone (Solu-medrol) was given in a 1 
gm bolus initially, then a tapering schedule was fol-
lowed reducing the dose from 200 mg/ day to 20 mg/ day 
by the sixth postoperative day. Most patients were 
maintained on 15 to 25 mg/ day of oral prednisone after 
the first week. If there was evidence of rejection, a 1 gm 
bolus of methylprednisolone, was administered. The 
steroid therapy was recycled as above. 
OKT3 (Ortho Pharmaceutical Corp., Raritan, N.].) 
(5 cc/day) was given to selected patients in whom rejec-
tion was documented by biopsy. In addition it was used 
as the major means of immunosuppression when pa-
tients on cyclosporin A were thought to have developed 
nephrotoxicity to that drug. In these cases the dosage of 
cyclosporin A could be lowered without risk of rejection. 
Three patients received azathioprine because of organ 
rejection refractory to cyclosporin A, steroids, and 
OKT3 or compromised renal function as a result of cy-
closporin A. 
Cefotaxime (1 gm every 6 hours) and ampicillin (1 
gm every 6 hours) were administered before operation 
and from 3 to 7 days after operation as a standard pro-
phylactic regimen for the liver transplant procedure as 
well as for biliary tract procedures after transplantation. 
Antibiotics and diet for selective bowel decontamination 
were not used during the study period. 
Statistical methods. Clinical and laboratory data 
were entered into the Prophet system (Division of Re-
search Resources, National Institutes of Health). Asso-
ciation of survival with clinical parameters and outcome 
was assessed by the chi-square and Fisher exact tests. 
RESULTS 
Demographics. During the 19-month study period 
363 liver transplant procedures were performed. Twen-
ty-three episodes of P. aeruginosa bacteremia occurred 
in 19 orthotopic liver transplant recipients during this 
study period (Table I). The mean age of the patients was 
46 years (range 24 to 67 years). Fifty two percent (12/ 
23) were graded as 2+ ill, and 48% (11/23) were graded 
4+ ill. 
The number of days between liver transplantation 
and onset of Pseudomonas bacteremia ranged from 3 to 
372 days (mean, 80 days; median 38 days). Five and two 
patients developed Pseudomonas bacteremia within 1 
and 2 weeks of transplantation, respectively, (Fig. 1). 
Sixty one percent (14/23) received a single transplant, 
whereas 39% (9/23) had received multiple transplants 
at the time of bacteremia. Two patients died within 7 
days after transplant surgery. More Pseudomonas bac-
teremias occurred in patients with Roux-en-Y biliary 
procedures 65% (15/23) as compared to choledocho-
holedochostomy (end to end) 35% (8/23). 
Ninety one percent (21/23) of the Pseudomonas bac-
teremias were nosocomial. The average length of hospi-
talization before the positive blood culture was 37 days. 
Only two patients were neutropenic (white blood cell 
counts were 1300 and 1700 cells/mm3) at the onset of 
bacteremia. 
Bacteriology. Polymicrobial bacteremia occurred in 
30% (7/23) of episodes; other organisms isolated in-
cluded Escherichia coli (one case), Streptococcus faeca-
lis (three cases), Enterobacter cloacae (two cases) and 
Staphylococcus epidermidis (one case). In 52% (11/21) 
of the patients, Pseudomonas was also isolated from the 
sputum; however, only eight of these patients were clin-
ically suspected of having pneumonia. 
Four patients had recurrent Pseudomonas bacteremia 
occurring at a range of 17 to 45 days after the first ep-
isode. One had a documented liver abscess, two had bil-
iary obstruction and presumed cholangitis, and one had 
a subhepatic abscess. 
Antibiotic therapy. Combination therapy consisting 
of an antipseudomonal beta-lactam antibiotic plus an 
aminoglycoside was administered to all patients. (Table 
I). In two cases the isolates were resistant in vitro to all 
aminoglycosides, and monotherapy with an anti-
pseudomonal agent was administered. Forty-three per-
cent (10/23) of the episodes were treated with oral 
rifampin (600 mg/three times a day) in addition to com-
bination tJ-lactam plus aminoglycoside therapy, as part 
of an experimental therapeutic protocol for P. aerugi-
nosa bacteremia.2 
Outcome. Seventy percent (16/23) of the cases were 
alive at 14 days after onset of bacteremia (Table I). Only 
26% (5/19, four patients had two episodes) were ulti-
mately discharged from the hospital; however, these 
discharged patients were all alive 12 months later. Of 
the four patients who had a repeat episode of 
Pseudomonas bacteremia, 50% (2/4) survived both ep-
isodes. Patients with polymicrobial bacteremia had a 
survival rate similar to those with P. aeruginosa bacte-
remia only (71 % [5/7] versus 69% [11/16]). 
Patients with hypotension, on mechanical ventilators, 
and severe illness as defined by objective criteria, had a 
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Table I. Twenty-three cases of Pseudomonas bacteremia in liver transplant recipients 
No. oj Status of 
Patient Underlying Portal trans- liver at Outcome 
(episode) Age disease Antibiotics OKT3 oj entry plants * time of +BC (14 days) 
5 (2) 41 Rejection of prior Imipenem, tobramycin, Yes Biliary 2 Mild rejection/ Lived 
liver rifampin liver abscess 
6 (1) 29 Chronic active Piperacillin, gentamicin Yes Abdominal 2 Portal vein Lived 
hepatitis thrombosis 
7 31 Unknown Piperacillin, Yes Unknown 1 Mild rejection/ Lived 
tobramycin CMV 
9 49 Cirrhosis Ceftazidime, Yes Biliary 2 Resolving Lived 
tobramycin, rifampin ischemia 
12 45 Crohns' disease Imipenem, tobramycin, Yes Pneumonia 2 Stable Lived 
rifampin 
16 34 Primary biliary Imipenem, amikacin, Yes Pneumonia 3 Rejection/CMV Lived 
cirrhosis rifampin hepatitis 
18 62 Cryptogenic cirrosis Mezlocillin, amikacin Yes Pneumonia 2 Stable Lived 
27 Hepatoma Piperacillin, No Pneumonia 2 Mild rejection Died 
tobramycin 
2 (1) 46 Hemophilia, AIDS Piperacillin, gentamicin No Pneumonia Rejection/CMV Lived 
2 (2) 46 AIDS Imipenem, amikacin No Abdominal 1 Rejection/CMV Died 
3 36 Portal vein Imipenem, tobramycin, No Unknown 1 Cholestasis Died 
thrombosis rifampin 
4 65 Alcoholic cirrhosis Piperacillin, No Unknown CMV hepatitis Died 
tobramycin, rifampin 
5 (1) 40 Chronic active Piperacillin, No Biliary Iliac vein Lived 
hepatitis tobramycin thrombosis 
6 (2) 29 Portal vein Piperacillin, No Abdominal 2 Portal vein Lived 
thrombosis tobramycin thrombosis 
8 24 Sclerosing cholangitis Imipenem, tobramycin, No Abdominal Rejection Lived 
rifampin 
10 67 Non-A, non-B Piperacillin, No Abdominal 3 Cholestasis Lived 
hepatitis tobramycin, rifampin 
11 39 Recurrent cholangitis Imipenem, tobramycin, No Abdominal 3 CMV hepatitis Lived 
rifampin 
13 47 Failure of 1 st Ciprofloxacin No Abdominal Abscess Lived 
transplant 
14 35 Budd-Chiari Ticarcillin, tobramycin No Pneumonia Rejection Died 
15 (1) 59 Cholangiocarcinoma Cefoperazone, amikacin No Pneumonia Recurrent Lived 
carcinoma 
15 (2) Cholangiocarcinoma Pi peracillin, No Unknown Recurrent Lived 
tobramycin carcinoma 
17 48 Non-A, non-B Mezlocillin, No Pneumonia 1 Cellular swelling Died' 
hepatitis gentamicin, rifampin 
19 60 Non-A, non-B Imipenem No Unknown Stable Died 
hepatitis 
AIDS, Acquired immunodeficiency syndrome; GMV, cytomegalovirus; BG, blood culture. 
• At the time of positive blood culture. 
significantly poorer outcome (Table II). Early admin- One-hundred percent (7/7) of patients with Pseudomo-
istration of antipseudomonal agents and the use of nas bacteremia who received OKT3 within 10 days of 
rifampin in addition to other antipseudomonal agents the onset of the bacteremia survived compared to 56% 
were associated with a 70% (7/10) survival at 14 days, (9/16) survival for those who did not (p = 0.057, Fish-
which was similar to standard therapy (69%, 9/13). er's exact test (Table III). Patients receiving OKT3 
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Fig. 1. Twenty-three episodes of bacteremia in 19 liver transplant recipients. Seven patients experienced bac-
teremia in the immediate postoperative period while receiving cefotaxime and ampicillin for prophylaxis. 
were more likely to have onset of bacteremia within 30 
days after transplant (86%, 6/7) as compared to greater 
than 30 days (14%, 1/7). 
No statistical difference was found in survival be-
tween the type of biliary or arterial anastomosis and 
outcome (Table IV). Fewer patients survived the epi-
sode of Pseudomonas bacteremia who were single organ 
recipients compared to multiple organ recipients. Death 
occurred at a mean of 12.6 and 22.5 days after positive 
blood cultures for single transplant and multiple trans-
plant recipients, respectively. 
Fig. 1 displays the time course from transplantation 
to Pseudomonas bacteremia to overall death/survival. 
Grouping the episodes by days from transplantation to 
onset of bacteremia revealed the following survival rates: 
day 0 to 30, 50% (5/10); day 30 to 60, 0% (0/4); days 
greater than 60, 11 % (1/9). Survival was more likely if 
the bacteremia occurred less than 30 days after opera-
tion (p = 0.052). Mortality in those patients with 
bacteremia occurring greater than 60 days after trans-
plantation was multifactorial and related to late com-
plications; for example, acquired immunodeficiency 
syndrome (AIDS), recurrent cholangiocarcinoma, cyto-
megalovirus hepatitis, and chronic rejection. 
Sixty percent (6/10) of episodes with onset of bacte-
remia less than 30 days after transplant were receiving 
ampicillin and cefotaxime at the time of Pseudomonas 
bacteremia ("superinfection"). Prior treatment with 
ampicillin and cefotaxime ranged from 3 to 7 days. 
Twenty percent (2/10) of patients with onset of bacte-
remia greater than 30 days received ampicillin and 
cefotaxime as empiric therapy for presumed infection. 
Pseudomonas bacteremia was documented in three 
patients with bile duct colonization. One occurred 
within 30 days, and two occurred greater than 60 days 
after transplantation. Two had undergone T-tube cho-
langiography before bacteremia with one receiving pre-
operative ampicillin and cefotaxime. The third patient 
had biliary obstruction from recurrent cholangiocarci-
noma. All three patients had a history of previous bile 
drainage from which P. aeruginosa was cultured. 
Both cases of neutropenia occurred in patients whose 
bacteremia occurred greater than 60 days after trans-
plantation; in one case, neutropenia was attributed to 
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Table II. Impact of clinical factors on survival of liver transplant recipients with Pseudomonas bacteremia 
Percentage 
Fever ?::39° C 100% 
Fever <39 0 C 65% 
Nosocomial infection 67% 
Community acquired 100% 
Portal of entry 
Abdominal/biliary 91% 
Other* 50% 
Hypotensive 14% 
Normotensive 94% 
Possible pneumonia 54% 
No pneumonia 65% 
Degree illnesst 
2+ 100% 
4+ 36% 
Neutropenia 0% 
No neutropenia 80% 
Diabetes mellitus 100% 
No diabetes mellitus 67% 
Serum creatinine :::; 1. 5 mg/ dl 100% 
Serum creatinine >1.5 mg/dl 63% 
Respiratory support 46% 
No respiratory support 100% 
Hemodialysis 60% 
No hemodialysis 72% 
NS, Not significant. 
·Pneumonia (7), unknown (5). 
tSee methods. 
cytomegalovirus hepatitis, whereas in the other case the 
cause was unknown. 
DISCUSSION 
P. aeruginosa is a well-established nosocomial patho-
gen typically associated with prolonged hospital stay 
and invasive procedures in severely ill and immuno-
compromised patients. Although promising new anti-
microbial agents are available, P. aeruginosa remains a 
difficult organism to treat; bacteremia caused by this 
organism carries a mortality rate significantly higher 
than for other bacterial pathogens. 
Bacteremias caused by P. aeruginosa have not ap-
peared to be problematic in early studies of infections in 
liver transplant recipients with only 0 to 9 episodes of 
P. aeruginosa bacteremia documented in four series.3-6 
In our study, 23 episodes of P. aeruginosa bacteremia 
No. survived/ 
total episodes p value 
3/3 NS 
13/20 
14/21 NS 
2/2 
10/11 NS (0.069) 
6/12 
1/7 0.0005 
15/16 
6/11 NS 
10/12 
12/12 0.001 
4/11 
0/2 NS (0.065) 
16/20 
2/2 NS 
14/21 
3/3 NS 
12/19 
6/13 0.007 
10/10 
3/5 NS 
13/18 
occurred in 19 patients-the largest collection of P. 
aeruginosa bacteremias in orthotopic liver transplant 
recipients ever reported. An episode of Pseudomonas 
bacteremia followed 6.6% (23/363) of liver transplant 
procedures. Interestingly, P. aeruginosa was second 
only to Staphylococcus aureus as a cause of bacteremia 
and constituted more than a sixth of all bacteremias. 
Neutropenia, a well-established risk factor for 
Pseudomonas bacteremia, was not a factor in this series 
in which only two patients were neutropenic. 
Previous studies have established that combination 
antibiotic therapy is preferred to monotherapy for 
Pseudomonas bacteremia.1,8 In this study survival was 
only slightly higher for patients who received combina-
tion therapy versus monotherapy (70% [14/20] versus 
66% [2/3]); however, the sample size was too small for 
optimal analysis. As expected, patients who were more 
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Table ill. Impact of medical therapies on survival of 
liver transplant recipients with Pseudomonas 
bacteremia 
Survival 
No. survived/ 
Percentage total episodes p value 
Steroids 73% 16/22 NS 
No steroids 0% 0/1 
Steroid bolus 82% 9/11 NS 
No bolus 58% 7/12 
Steroid recycle 80% 4/5 NS 
No recycle 67% 12/18 
Azathioprine 100% 3/3 
No azathioprine 65% 13/20 NS 
OKT3 100% 7/7 NS (0.057) 
No OKT3 56% 9/16 
Antipseudomonal 
agents 
Within 48 hr 68% 15/22 
of positive 
blood culture 
Greater than 48 hr 100% 1/1 NS 
ill as graded by objective criteria at the time of bacter-
emia had significantly poorer outcome. 
The precise cause of death was difficult to ascertain 
in these patients with multifactorial medical problems. 
We chose to evaluate death at a fixed end point in time, 
rather than making a subjective assessment; the as-
sumption was that death within 14 days after the pos-
itive blood culture was likely related to Pseudomonas 
bacteremia. The overall mortality rate was 30% (7/23) 
at day 14. Death at a later date was due to complicated 
medical conditions including rejection, liver failure, cy-
tomegalovirus hepatitis, AIDS, and recurrent tumor 
(Table I). 
Orthoclone OKT3, a murine monoclonal antibody, 
which blocks the generation and function of human cy-
totoxic T cells, has improved both allograft and patient 
survival.9 Surprisingly, we found an increased survival 
for patients who received OKT3 within 10 days of 
Pseudomonas bacteremia. The basis for this finding is 
unclear. 
Ampicillin and cefotaxime have been routinely used 
in our institution for prophylaxis and empiric treatment 
of presumed infection in liver transplant recipients, but 
neither has antipseudomonal activity. These antibiotics 
may actually promote the emergence of P. aeruginosa. 
In 30.4% (7/23) of the patients, the Pseudomonas bac-
Table IV. Impact of surgical procedures on outcome 
survival of liver transplant recipients with 
Pseudomonas bacteremia 
Arterial procedure 
Arterial conduit 
End-to-end 
Biliary procedure 
Roux-en-Y 
End-to-end 
No. of transplants* 
Single 
Multiple 
Previous biliary surgery 
No previous biliary surgery 
Stints at OR 
No stints at OR 
OR, Operating room. 
* At time of positive blood culture. 
Survival (at 14 days) 
No survival/ p 
Percentage total episodes value 
60% 3/5 NS 
72% 13/18 
67% 10/15 NS 
75% 6/8 
57% 8/14 NS 
89% 8/9 
85% 11/13 NS 
50% 5/10 
83% 5/6 NS 
65% 11/17 
teremia could be classified as immediate postoperative 
"superinfection," since these patients received the pro-
phylactic antibiotics of ampicillin and cefotaxime dur-
ing surgery and in the postoperative period. In two other 
patients, bacteremia followed T -tube cholangiography; 
both of these patients had prior colonization with P. 
aeruginosa, and one received preprocedure ampicillin 
and cefotaxime. Finally, one patient in whom bactere-
mia occurred between 30 to 60 days after transplanta-
tion was receiving ampicillin and cefotaxime empiri-
cally at the time of sepsis. 
This study suggests that selection of prophylactic an-
tibiotics before transplant or biliary tract manipulation 
should include agents with in vitro activity against P. 
aeruginosa; options include piperacillin, imipenem, 
ceftazidime, and ciprofloxacin. Of the Pseudomonas 
bacteremias reported here 43.3% (10/23) might have 
been prevented if antipseudomonal antibiotics had been 
used in the prophylactic regimen. On the other hand, 
since the administration of more potent antibiotics might 
lead to emergence of other more resistant organisms, a 
controlled trial comparing the current prophylactic reg-
imen versus a regimen that includes antipseudomonal 
agents is likely indicated. 
Certainly, antipseudomonal antibiotics should be 
used for infected patients with known Pseudomonas 
biliary colonization. Finally, empiric antibiotic therapy 
for presumed bacterial infection in selected liver trans-
plant recipients might also include antipseudomonal 
agents. 
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